Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections
The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers. We conducted causal mediation analy...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 2024-07, Vol.230 (1), p.152-160 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 160 |
|---|---|
| container_issue | 1 |
| container_start_page | 152 |
| container_title | The Journal of infectious diseases |
| container_volume | 230 |
| creator | Lim, Wey Wen Feng, Shuo Wong, Sook-San Sullivan, Sheena G Cowling, Benjamin J |
| description | The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.
We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.
The proportions of vaccine efficacy mediated by postvaccination HAI titers were estimated to be 22% (95% confidence interval, 18%--47%) for influenza A(H1N1), 20% (16%-39%) for influenza A(H3N2), and 37% (26%-85%) for influenza B/Victoria.
HAI titers partially mediate influenza vaccine efficacy against influenza A(H1N1), A(H3N2), and B/Victoria. Our estimates were lower than in previous studies, possibly reflecting expected heterogeneity in antigenic similarity between vaccine and circulating viruses across seasons. |
| doi_str_mv | 10.1093/infdis/jiae122 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3084771657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3084771657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c180t-429d318f5563991d5896f3f70d9dc0d3e4990a7f6a55baf51d462e16f58a04593</originalsourceid><addsrcrecordid>eNpNkU1P20AQhldVUQnQa4_VHqmEya7Xu_YeA6IECcKBwNWa7Ec6yF6n3vUh_UH9nXVIijjNO9Izj0Z6CfnG2SVnWkwxeItx-orgeJ5_IhMuRZkpxcVnMmEszzNeaX1MTmJ8ZYwVQpVfyLHQTOalKCbk79y1sF43Q8IACbtA78IvXOFbnIWEq85u6RKT6yOFSB-cRUjduHR-RH0zuPAH6AsYg8HRG-_RgNnS2RowxESftu0mde2oNh_w2fmcL_iPi10Qi3wMECy9mr6gGd04-rAf4u7Amd0n8YwceWii-3qYp-T5583yep7dP97eXc_uM8MrlrIi11bwykuphNbcykorL3zJrLaGWeEKrRmUXoGUK_CS20LljisvK2CF1OKUnO-9m777PbiY6hajcU0DwXVDrAWrirLkSpYjerlHTd_F2Dtfb3psod_WnNW7bup9N_Whm_Hg-8E9rFpn3_H_ZYh_IsaNBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084771657</pqid></control><display><type>article</type><title>Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Lim, Wey Wen ; Feng, Shuo ; Wong, Sook-San ; Sullivan, Sheena G ; Cowling, Benjamin J</creator><creatorcontrib>Lim, Wey Wen ; Feng, Shuo ; Wong, Sook-San ; Sullivan, Sheena G ; Cowling, Benjamin J</creatorcontrib><description>The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.
We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.
The proportions of vaccine efficacy mediated by postvaccination HAI titers were estimated to be 22% (95% confidence interval, 18%--47%) for influenza A(H1N1), 20% (16%-39%) for influenza A(H3N2), and 37% (26%-85%) for influenza B/Victoria.
HAI titers partially mediate influenza vaccine efficacy against influenza A(H1N1), A(H3N2), and B/Victoria. Our estimates were lower than in previous studies, possibly reflecting expected heterogeneity in antigenic similarity between vaccine and circulating viruses across seasons.</description><identifier>ISSN: 0022-1899</identifier><identifier>ISSN: 1537-6613</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/jiae122</identifier><identifier>PMID: 39052734</identifier><language>eng</language><publisher>United States</publisher><subject>Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Child ; Child, Preschool ; Female ; Hemagglutination Inhibition Tests ; Humans ; Infant ; Influenza A Virus, H1N1 Subtype - immunology ; Influenza A Virus, H3N2 Subtype - immunology ; Influenza B virus - immunology ; Influenza Vaccines - administration & dosage ; Influenza Vaccines - immunology ; Influenza, Human - immunology ; Influenza, Human - prevention & control ; Male ; Vaccine Efficacy ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - immunology</subject><ispartof>The Journal of infectious diseases, 2024-07, Vol.230 (1), p.152-160</ispartof><rights>The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c180t-429d318f5563991d5896f3f70d9dc0d3e4990a7f6a55baf51d462e16f58a04593</cites><orcidid>0000-0002-6297-7154</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39052734$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Wey Wen</creatorcontrib><creatorcontrib>Feng, Shuo</creatorcontrib><creatorcontrib>Wong, Sook-San</creatorcontrib><creatorcontrib>Sullivan, Sheena G</creatorcontrib><creatorcontrib>Cowling, Benjamin J</creatorcontrib><title>Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.
We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.
The proportions of vaccine efficacy mediated by postvaccination HAI titers were estimated to be 22% (95% confidence interval, 18%--47%) for influenza A(H1N1), 20% (16%-39%) for influenza A(H3N2), and 37% (26%-85%) for influenza B/Victoria.
HAI titers partially mediate influenza vaccine efficacy against influenza A(H1N1), A(H3N2), and B/Victoria. Our estimates were lower than in previous studies, possibly reflecting expected heterogeneity in antigenic similarity between vaccine and circulating viruses across seasons.</description><subject>Antibodies, Viral - blood</subject><subject>Antibodies, Viral - immunology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Female</subject><subject>Hemagglutination Inhibition Tests</subject><subject>Humans</subject><subject>Infant</subject><subject>Influenza A Virus, H1N1 Subtype - immunology</subject><subject>Influenza A Virus, H3N2 Subtype - immunology</subject><subject>Influenza B virus - immunology</subject><subject>Influenza Vaccines - administration & dosage</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza, Human - immunology</subject><subject>Influenza, Human - prevention & control</subject><subject>Male</subject><subject>Vaccine Efficacy</subject><subject>Vaccines, Inactivated - administration & dosage</subject><subject>Vaccines, Inactivated - immunology</subject><issn>0022-1899</issn><issn>1537-6613</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkU1P20AQhldVUQnQa4_VHqmEya7Xu_YeA6IECcKBwNWa7Ec6yF6n3vUh_UH9nXVIijjNO9Izj0Z6CfnG2SVnWkwxeItx-orgeJ5_IhMuRZkpxcVnMmEszzNeaX1MTmJ8ZYwVQpVfyLHQTOalKCbk79y1sF43Q8IACbtA78IvXOFbnIWEq85u6RKT6yOFSB-cRUjduHR-RH0zuPAH6AsYg8HRG-_RgNnS2RowxESftu0mde2oNh_w2fmcL_iPi10Qi3wMECy9mr6gGd04-rAf4u7Amd0n8YwceWii-3qYp-T5583yep7dP97eXc_uM8MrlrIi11bwykuphNbcykorL3zJrLaGWeEKrRmUXoGUK_CS20LljisvK2CF1OKUnO-9m777PbiY6hajcU0DwXVDrAWrirLkSpYjerlHTd_F2Dtfb3psod_WnNW7bup9N_Whm_Hg-8E9rFpn3_H_ZYh_IsaNBg</recordid><startdate>20240725</startdate><enddate>20240725</enddate><creator>Lim, Wey Wen</creator><creator>Feng, Shuo</creator><creator>Wong, Sook-San</creator><creator>Sullivan, Sheena G</creator><creator>Cowling, Benjamin J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6297-7154</orcidid></search><sort><creationdate>20240725</creationdate><title>Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections</title><author>Lim, Wey Wen ; Feng, Shuo ; Wong, Sook-San ; Sullivan, Sheena G ; Cowling, Benjamin J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c180t-429d318f5563991d5896f3f70d9dc0d3e4990a7f6a55baf51d462e16f58a04593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Viral - blood</topic><topic>Antibodies, Viral - immunology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Female</topic><topic>Hemagglutination Inhibition Tests</topic><topic>Humans</topic><topic>Infant</topic><topic>Influenza A Virus, H1N1 Subtype - immunology</topic><topic>Influenza A Virus, H3N2 Subtype - immunology</topic><topic>Influenza B virus - immunology</topic><topic>Influenza Vaccines - administration & dosage</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza, Human - immunology</topic><topic>Influenza, Human - prevention & control</topic><topic>Male</topic><topic>Vaccine Efficacy</topic><topic>Vaccines, Inactivated - administration & dosage</topic><topic>Vaccines, Inactivated - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lim, Wey Wen</creatorcontrib><creatorcontrib>Feng, Shuo</creatorcontrib><creatorcontrib>Wong, Sook-San</creatorcontrib><creatorcontrib>Sullivan, Sheena G</creatorcontrib><creatorcontrib>Cowling, Benjamin J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Wey Wen</au><au>Feng, Shuo</au><au>Wong, Sook-San</au><au>Sullivan, Sheena G</au><au>Cowling, Benjamin J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>2024-07-25</date><risdate>2024</risdate><volume>230</volume><issue>1</issue><spage>152</spage><epage>160</epage><pages>152-160</pages><issn>0022-1899</issn><issn>1537-6613</issn><eissn>1537-6613</eissn><abstract>The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.
We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.
The proportions of vaccine efficacy mediated by postvaccination HAI titers were estimated to be 22% (95% confidence interval, 18%--47%) for influenza A(H1N1), 20% (16%-39%) for influenza A(H3N2), and 37% (26%-85%) for influenza B/Victoria.
HAI titers partially mediate influenza vaccine efficacy against influenza A(H1N1), A(H3N2), and B/Victoria. Our estimates were lower than in previous studies, possibly reflecting expected heterogeneity in antigenic similarity between vaccine and circulating viruses across seasons.</abstract><cop>United States</cop><pmid>39052734</pmid><doi>10.1093/infdis/jiae122</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6297-7154</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 2024-07, Vol.230 (1), p.152-160 |
| issn | 0022-1899 1537-6613 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3084771657 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current) |
| subjects | Antibodies, Viral - blood Antibodies, Viral - immunology Child Child, Preschool Female Hemagglutination Inhibition Tests Humans Infant Influenza A Virus, H1N1 Subtype - immunology Influenza A Virus, H3N2 Subtype - immunology Influenza B virus - immunology Influenza Vaccines - administration & dosage Influenza Vaccines - immunology Influenza, Human - immunology Influenza, Human - prevention & control Male Vaccine Efficacy Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - immunology |
| title | Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T01%3A09%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hemagglutination%20Inhibition%20Antibody%20Titers%20as%20Mediators%20of%20Influenza%20Vaccine%20Efficacy%20Against%20Symptomatic%20Influenza%20A(H1N1),%20A(H3N2),%20and%20B/Victoria%20Virus%20Infections&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Lim,%20Wey%20Wen&rft.date=2024-07-25&rft.volume=230&rft.issue=1&rft.spage=152&rft.epage=160&rft.pages=152-160&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/jiae122&rft_dat=%3Cproquest_cross%3E3084771657%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3084771657&rft_id=info:pmid/39052734&rfr_iscdi=true |